Furthermore, knocking out genes that drive neurotoxicity and CRS, such as GM-CSF and IL-6 [43], using CRISPR-Cas9 editing, may result in potent and persistent cell therapies. This evidence concerns the gene CSF2 and congenital rubella syndrome.